Eisai Taps Novartis Oncology Firepower For Lenvima
This article was originally published in PharmAsia News
Following the recent approval of Lenvima for kidney cancer in the US, Eisai has allied with major oncology player Novartis to help drive sales of the product in this market.
You may also be interested in...
Eisai’s lenvatinib is endorsed by an expert panel in India in combination with everolimus, for which multiple generic brands are available in addition to Novartis’ Afinitor. The Swiss multinational isn’t allying with Eisai in India at least for now.
During its July 2016 meeting, the EU's top scientific advisory panel, the Committee for Medicinal Products for Human Use, recommended approval for two anticancers, cabozantinib and lenvatinib, that will likely shake up the advanced kidney cancer sector, and a new therapy for pancreatic cancer, liposomal and pegylated irinotecan.
Plus deals involving Takeda/Puma, SillaJen/Basilea, Celltrion/Abpro, METiS/Voronoi, Yuhan/AtoGen, Biocytogen/FineImmune and Avance/C3.